Apollomics (NASDAQ:APLM) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Apollomics (NASDAQ:APLM) from a hold rating to a sell rating in a research report report published on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Apollomics Price Performance

Shares of NASDAQ APLM opened at $22.24 on Friday. Apollomics has a twelve month low of $3.66 and a twelve month high of $42.12. The firm has a 50-day moving average of $17.30 and a two-hundred day moving average of $12.56.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.